Search results for " THROMBOSIS"

showing 10 items of 328 documents

Percutaneous Femoropopliteal Bypass: 2-Year Results of the DETOUR System

2021

Purpose: This study investigated the 2-year safety and effectiveness of the PQ Bypass DETOUR system as a percutaneous femoropopliteal bypass. Materials and Methods: Seventy-eight patients with 82 long-segment femoropopliteal lesions were enrolled in this prospective, single-arm, multicenter study. The DETOUR system deployed Torus stent grafts directed through a transvenous route. Eligible patients included those with lesions of >10 cm and average of 371±55 mm. Key safety endpoints included major adverse events (MAEs) and symptomatic deep venous thrombosis in the target limb. Effectiveness endpoints included primary patency defined as freedom from ≥50% stenosis, occlusion, or clinically-d…

medicine.medical_specialtyPercutaneousmedicine.medical_treatmentLesionPeripheral Arterial DiseaseOcclusionmedicineHumansPopliteal ArteryRadiology Nuclear Medicine and imagingProspective StudiesAdverse effectVascular Patencybusiness.industryEndovascular ProceduresStentmedicine.diseaseSurgeryFemoral ArteryVenous thrombosisStenosisTreatment OutcomeStentsSurgerymedicine.symptomCardiology and Cardiovascular MedicinebusinessClaudicationJournal of Endovascular Therapy
researchProduct

Thrombosis

2014

Background— Thrombosis is the common pathology underlying ischemic heart disease, ischemic stroke, and venous thromboembolism (VTE). The Global Burden of Disease Study 2010 (GBD 2010) documented that ischemic heart disease and stroke collectively caused 1 in 4 deaths worldwide. GBD 2010 did not report data for VTE as a cause of death and disability. Objective— To review the literature on the global burden of disease caused by VTE. Approach and Results— We performed a systematic review of the literature on the global disease burden because of VTE in low-, middle-, and high-income countries. Studies from Western Europe, North America, Australia, and Southern Latin America (Argentina) yielded…

medicine.medical_specialtyPopulation ageingPopulationMyocardial IschemiaDisease030204 cardiovascular system & hematologyGlobal HealthCohort Studies03 medical and health sciencesLife Expectancy0302 clinical medicineCost of IllnessCause of DeathEnvironmental healthGlobal healthPrevalenceHumansMedicinecardiovascular diseases030212 general & internal medicineIntensive care medicineeducationStrokeDisease burdenCause of deathVenous Thrombosiseducation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)Racial GroupsAge FactorsThrombosisVenous ThromboembolismHematologymedicine.diseaseThrombosis3. Good healthStrokePneumoniaVenous thrombosisSocial ClassQuality-Adjusted Life YearsMedical emergencyPulmonary EmbolismCardiology and Cardiovascular MedicinebusinessArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Comparación de las frecuencias de los alelos factor V Leiden (G1691A) y protrombina-G20210A entre pacientes con trombosis venosa profunda y población…

2006

Background: Factor V leiden and the -G20210A variant of prothrombin gene are associated to a higher risk of deep venous thrombosis. Aim: To assess the frequency of factor V Leiden (G1691A) and prothrombin -G20210A alleles in patients with deep venous thrombosis (DVT) and in the general population from Spain. Material and methods: Factor V Leiden (g1691a) and prothrombin-g20210a alleles were genotyped in 493 individuals from the Spanish general populations and in 131 patients with DVT. The presence of DVT was confirmed by phlebography. Allelic frequencies and the DVT risk associated with these variants were estimated. Results: Allelic frequencies for the factor V Leiden (G1691A) allele were …

medicine.medical_specialtyPopulationGastroenterologyInternal medicinehemic and lymphatic diseasesGenotypeG20210AVenous thrombosismedicineFactor V Leidencardiovascular diseasesAlleleeducationAlleleseducation.field_of_studyFactor V Leidenbusiness.industryGeneral MedicineOdds ratiomedicine.diseaseConfidence intervalSurgeryVenous thrombosisProthrombin geneProthrombin G20210Abusiness
researchProduct

Sequentielle transarterielle Chemoembolisation (TACE) des hepatozellulären Karzinoms (HCC) - Erfahrungsbericht eines einzelnen Zentrums über 5 Jahre

2007

PURPOSE: To analyze the course of disease of patients treated with sequential TACE and to evaluate the dependent and independent prognostic factors for patient survival using the Cox Proportional Hazard Model. MATERIALS AND METHODS: 94 patients palliatively treated with TACE. Patients were selected if they had been treated at least 3 times. The TACE procedure was carried out at 8-week intervals using a suspension consisting of a fixed dosage of Mitomycin C (10 mg) and 10 ml Lipiodol. Follow-up investigations included contrast-enhanced multislice CT before and after TACE and assessment of the laboratory test results (i. e., blood count, liver enzymes, and coagulation). RESULTS: In 66.7 % of …

medicine.medical_specialtyProportional hazards modelbusiness.industrymedicine.diseaseSingle CenterGastroenterologyPortal vein thrombosisTumor progressionInternal medicineHepatocellular carcinomaAscitesmedicineLipiodolRadiology Nuclear Medicine and imagingRadiologyLiver functionmedicine.symptombusinessmedicine.drugRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
researchProduct

Risk of Recurrence After a First Episode of Symptomatic Venous Thromboembolism Provoked by a Transient Risk Factor A Systematic Review

2010

Background We aimed to determine the risk of recurrence for symptomatic venous thromboembolism (VTE) provoked by different transient risk factors. Data Sources MEDLINE, EMBASE, and Cochrane Collaboration Registry of Randomized Trials databases were searched. Study Selection Prospective cohort studies and randomized trials of patients with a first episode of symptomatic VTE provoked by a transient risk factor and treated for at least 3 months were identified. Data Extraction Number of patients and recurrent VTE during the 0- to 12-month and 0- to 24-month intervals after stopping therapy, study design, and provoking risk factor characteristics were extracted. Data Synthesis Annualized recurr…

medicine.medical_specialtyRate ratioRisk Assessmentlaw.inventionRandomized controlled triallawRecurrenceRisk FactorsInternal medicineEpidemiologyInternal MedicinemedicineHumansRisk factorProspective cohort studyFirst episodebusiness.industryIncidence (epidemiology)IncidenceVenous Thromboembolismvenous thrombosis recurrent eventmedicine.diseasePrognosisSurgeryVenous thrombosisbusiness
researchProduct

The role of portal vein thrombosis in the clinical course of inflammatory bowel diseases: report on three cases and review of the literature.

2012

Inflammatory bowel diseases are associated with an increased risk of vascular complications. The most important are arterial and venous thromboembolisms, which are considered as specific extraintestinal manifestations of inflammatory bowel diseases. Among venous thromboembolism events, portal vein thrombosis has been described in inflammatory bowel diseases. We report three cases of portal vein thrombosis occurring in patients with active inflammatory bowel disease. In two of them, hepatic abscess was present. Furthermore, we performed a systematic review based on the clinical literature published on this topic.

medicine.medical_specialtySettore MED/09 - Medicina InternaHepatologybusiness.industryGastroenterologyClinical courseInflammatory Bowel DiseasesReview ArticleClinical literaturemedicine.diseaseGastroenterologyInflammatory bowel diseasePortal vein thrombosisIncreased riskInternal medicineportal thrombosis.inflammatory bowel diseaseMedicineIn patientlcsh:Diseases of the digestive system. Gastroenterologylcsh:RC799-869businessVenous thromboembolism
researchProduct

C0307 Baseline characteristics and management of patients with splanchnic vein thrombosis: Results of an international registry

2012

medicine.medical_specialtySplanchnic vein thrombosisbusiness.industryInternal medicineBaseline characteristicsmedicineCardiologyHematologybusinessSurgeryThrombosis Research
researchProduct

C0322 Factors associated with therapeutic strategies in patients with splanchnic vein thrombosis: Results of an international registry

2012

medicine.medical_specialtySplanchnic vein thrombosisbusiness.industryInternal medicineCardiologymedicineIn patientHematologybusinessThrombosis Research
researchProduct

Evaluation of direct oral anticoagulants in superficial-vein thrombosis – Authors' reply

2017

medicine.medical_specialtySuperficial vein thrombosisbusiness.industryMEDLINEHematology030204 cardiovascular system & hematologymedicine.diseaseThrombosisSurgery03 medical and health sciencesVenous thrombosis0302 clinical medicinemedicine030212 general & internal medicinebusinessThe Lancet Haematology
researchProduct

The long road for tailored STEMI strategies but a short path for thrombus aspiration

2020

medicine.medical_specialtyThrombus aspirationbusiness.industryCoronary ThrombosisElectrocardiographyPercutaneous Coronary InterventionPath (graph theory)HumansST Elevation Myocardial InfarctionMedicineRadiologyCardiology and Cardiovascular MedicinebusinessThrombectomyInternational Journal of Cardiology
researchProduct